



Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

October 14, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 14, 2022-- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 6th Annual NASH Investor Conference taking place virtually on October 17th, 2022.

Details for the fireside chat are as follows:

Date: Monday, October 17th, 2022

Time: 3:00 pm Eastern Time

Webcast: <https://journey.ct.events/view/6b38c477-2942-428b-aed6-b4f7a0dcea88>

The webcast will be accessible in the Investors & News section on the company's website at www.axcellatx.com. An archive of the webcast replay will be available on the Company's website for up to 90 days.

To request a one-on-one virtual meeting, please contact meetings@hcwco.com.

Internet Posting of Information

Axcella uses the "Investors and News" section of its website, www.axcellatx.com, as a means of disclosing material nonpublic information, to communicate with investors and the public, and for complying with its disclosure obligations under Regulation FD. Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts. The information that we post on our website could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

About Axcella Therapeutics (Nasdaq: AXLA)

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The company's product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella's pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and NASH. The company's unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221014005467/en/): <https://www.businesswire.com/news/home/20221014005467/en/>

LifeSci Advisors

Ashley Robinson

arr@lifesciadvisors.com

(617) 430-7577

Source: Axcella Therapeutics